Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | HTT | P42858 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21268441 | 0.90 | NQO1 (0.42) | GPR3MAPTALDH1A1CYP2C9CYP17A1 | |
| SCHEMBL21268362 | 0.87 | MAPT (0.34) | GPR3MAPTALDH1A1CYP2C9CYP17A1 | |
| SCHEMBL883938 | 0.87 | PTGS1 (0.39) | GPR3MAPTALDH1A1CYP2C9CYP17A1 | |
| SCHEMBL17046293 | 0.81 | GPR3 (0.45) | GPR3MAPTALDH1A1CYP2C9CYP17A1 | |
| SCHEMBL3278789 | 0.81 | ALDH1A1 (0.33) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5437045 | 0.81 | MAPT (0.36) | MAPTALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL21268318 | 0.79 | ALDH1A1 (0.32) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL21268273 | 0.79 | ALDH1A1 (0.32) | MAPTALDH1A1CYP2C9CYP17A1CYP2C19 | |
| SCHEMBL161038 | 0.79 | SMN1; SMN2 (0.35) | MAPTALDH1A1CYP2C9CYP17A1CYP2C19 | |
| SCHEMBL21268177 | 0.77 | HDAC4 (0.31) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10576086-B2 | Triazine derivatives as interferon-gamma inhibitors | UNIVERSITY OF GREENWICH (GB) | 2020-03-03 | — | — | US | claimed |
| US-20180169105-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIVERSITY OF GREENWICH (GB) | 2018-06-21 | — | — | US | claimed |
| EP-3307273-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | University of Greenwich (GB) | 2018-04-18 | — | — | EP | claimed |
| WO-2016198878-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | UNIVERSITY OF GREENWICH (GB) | 2016-12-15 | — | — | WO | claimed |
| EP-2427058-B1 | NEMATOCIDAL SULFONAMIDES | DU PONT (US) | 2014-12-31 | — | — | EP | claimed |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-08-07 | — | — | US | claimed |
| US-8623890-B2 | Nematocidal sulfonamides | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-01-07 | — | — | US | claimed |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-05-10 | — | — | US | claimed |
| EP-2427058-A2 | NEMATOCIDAL SULFONAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-03-14 | — | — | EP | claimed |
| WO-2010129500-A2 | NEMATOCIDAL SULFONAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-11 | — | — | WO | claimed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | claimed |
| CN-1860114-A | Benzoxazinone-derived sulfonamide compounds, process for their preparation and their use as pharmaceuticals | ESTEVE LABOR DR (ES) | 2006-11-08 | — | — | CN | claimed |
| EP-1648886-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2005014589-A1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | claimed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | claimed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | claimed |
| US-6136825-A | ANTIDEPRESSANTS AND CENTRAL NERVOUS SYSTEM AGENTS | KNOLL AKTIENGESELLSCHAFT | 2000-10-24 | — | — | US | claimed |
| EP-0948498-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-13 | — | — | EP | claimed |
| WO-1998029411-A1 | SULFONAMIDE COMPOUNDS HAVING 5-HT RECEPTOR ACTIVITY | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-07-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | GPR3 4306/4885MAPT 3069/4885ALDH1A1 53/4885 |
| US-20140221203-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | GPR3 1914/4885MAPT 4833/4885ALDH1A1 2283/4885 |
| US-20120114624-A1 | NEMATOCIDAL SULFONAMIDES | NSFL1C, QSOX1, Q6ZSR9 | GPR3 1914/4885MAPT 4833/4885ALDH1A1 2283/4885 |
| US-10576086-B2 | Triazine derivatives as interferon-gamma inhibitors | IFNG, IFNAR1, IRF3 | GPR3 2186/4885MAPT 18/4885ALDH1A1 1809/4885 |
| US-20180169105-A1 | TRIAZINE DERIVATIVES AS INTERFERON-GAMMA INHIBITORS | IFNG, IFNAR1, IRF3 | GPR3 2186/4885MAPT 18/4885ALDH1A1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.